SUNNYVALE, Calif., Sept. 19 /PRNewswire-FirstCall/ --
Scios, Inc. (Nasdaq: SCIO) today announced that 15 abstracts related to
Natrecor(R) (nesiritide), are being presented next week at the Sixth Annual
Scientific Meeting of the Heart Failure Society of America (HFSA), the premier
meeting of clinicians that treat heart failure in the United States.
"This meeting is a great opportunity for clinicians to learn more about
the continued research being conducted with Natrecor, and to answer some of
their questions as they incorporate Natrecor into everyday practice," said
Darlene P. Horton, M.D., Vice President of Medical Affairs at Scios. "Of
particular interest are studies that discuss the positive effects of Natrecor
on coronary artery vasodilation and cardiac performance in both acute and
chronic settings and its potential for pharmacoeconomic benefits."
Several abstracts describing the unique pharmacologic properties of BNP
(B-type natriuretic peptide) also will be presented by members of Dr. John
Burnett's laboratory at the Mayo Clinic.
"BNP has long been recognized as an important cardiac hormone. The
availability of BNP as both a diagnostic and a therapeutic has escalated
important research on the role of BNP in the prevention and treatment of
various forms of heart disease," added Dr. Horton.
Scios also is supporting two CME-accredited satellite symposia during the
meeting. The first, entitled "Emerging Heart Failure Management Strategies
from a New Drug Class," will take place on Sunday, Sept. 22, from
1:00 - 3:00 p.m. ET. The second symposium, entitled "The Role of BNP for
Diagnosis and Management of Heart Failure," will take place on Monday,
Sept. 23, from 6:30 - 8:00 a.m. ET.
On Monday, September 23, the following posters will be available for
viewing from 10:00 a.m. until 7:00 p.m. ET. Oral presentations by the authors
will occur between 5:45 and 6:45 p.m. ET.
#059: Effects of Intravenous Nesiritide on Coronary Vasomotor Regulation
and Myocardial Oxygen Consumption, Andrew D. Michaels, M.D., et al; University
of California, San Francisco, San Francisco, CA
#175: ADHERE (Acute Decompensated Heart Failure National Registry):
Rationale, Design, and Subject Population, Gregg C. Fonarow, et al, for the
ADHERE Scientific Advisory Committee and Investigators; Ahmanson-UCLA
Cardiomyopathy Center, Los Angeles, CA
#176: The Effects of Nesiritide on Serum Levels of B-Type Natriuretic
Peptide (BNP) in Patients Admitted for Decompensated Congestive Heart Failure,
Alan S. Maisel, M.D., et al; San Diego VA Healthcare Center, San Diego, CA
#177: A Pilot Study of the Safety and Efficacy of Nesiritide in the
Management of Acute Decompensated Congestive Heart Failure Complicated by an
Acute Coronary Syndrome, W. Frank Peacock, M.D., et al; The Cleveland Clinic,
Cleveland, OH
#187: Management of Patients with Congestive Heart Failure after
Hospitalization -- Follow Up Serial Infusions of Nesiritide (FUSION):
Clinical Trial Design, Marc A. Silver, M.D., et al, for the FUSION Scientific
Advisory Committee; Advocate Christ Medical Center, Oak Lawn, IL
#235: Early Adoption and Use of Nesiritide in the Treatment of
Hospitalized Heart Failure Patients, Benjamin Gutierrez, Ph.D., et al;
Pharmaceutical Research Services, Premier, Inc., Charlotte, NC
#248: Autonomic Dysfunction in Hospitalized Patients with Decompensated
Heart Failure Can Predict Survival After Discharge, Doron Aronson, M.D., et
al; Rambam Medical Center, Haifa, Israel
On Tuesday, September 24, the following posters will be available for
viewing from 10:00 a.m. until 7:00 p.m. ET. Oral presentations by the authors
will occur between 5:45 and 6:45 pm ET.
#119: Endothelin Levels in Hospitalized Patients With Decompensated Heart
Failure Predict Short-Term Survival After Discharge, Doron Aronson, M.D., et
al; Rambam Medical Center, Haifa, Israel
#153: Serum Levels of B-Type Natriuretic Peptide After Cardiectomy and
Implantation of a Total Artificial Heart, Reynolds M. Delgado III, M.D., et
al; Cardiopulmonary Transplantation, Texas Heart Institute/St. Luke's
Episcopal Hospital, Houston, TX
#204: Safety of Nesiritide During Infusion For Decompensated Heart
Failure, W. Frank Peacock, M.D., et al; The Cleveland Clinic, Cleveland, OH
#205: Nesiritide in an Outpatient Infusion Clinic Setting -- Case Studies
of 17 Patients, Larry Altschul M.D., et al; South Bay Cardiovascular
Associates, West Islip, NY
#221: Cost-Effectiveness of Nesiritide in Acute Decompensated Heart
Failure, Claire B. Hunter, M.D., et al; Creighton University Schools of
Pharmacy and Allied Health Professions, Omaha, NE
#224: Decreased Filling Pressures by Nesiritide Infusions in
Non-Decompensated Congestive Heart Failure Patients, Tom Bennett, M.D., et al;
Heart Failure Management, Medtronic, Inc., Minneapolis, MN
#335: Intermittent Out-Patient Nesiritide Infusion is an Effective
Alternative to Hospital Admission for the Treatment of Decompensated Heart
Failure, John S. Golden, M.D., et al; Department of Cardiology, Kaiser
Permanente of the Mid-Atlantic States, Fairfax, VA
#351: Efficacy and Safety of Combined Nesiritide and Milrinone in the
Treatment of Acutely Decompensated Heart Failure, Nandkishore R. Gurram, M.D.,
et al; Division of Cardiovascular Medicine, University of Kentucky, Lexington,
KY
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for
cardiovascular and inflammatory disease. The Company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
Forward-Looking Safe Harbor Statement
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We generally identify such forward-looking statements
using words like "estimate," "believe," "intend," "expect," "may," "should,"
"plan," "project," "contemplate," "anticipate" or similar statements.
Statements that are not historical facts are forward-looking statements based
on current assumptions that involve risks and uncertainties. These risks and
uncertainties may include the sales penetration and success of Natrecor, the
success of clinical trials of Natrecor and our pipeline products, including
SCIO-469 and inhibitors to TGF-beta, our ability to partner the development
and commercialization of our pipeline products and Natrecor (outside the U.S.
and Europe) with third parties on favorable terms, or at all, as well as other
risks detailed from time to time in the reports filed by Scios with the SEC,
including the Company's quarterly reports and annual report on Form 10-K.
Actual results, performance or achievements of Scios may differ significantly
from those described in these forward-looking statements. Scios disclaims any
intention or obligation to update or revise any financial projections or
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE Scios, Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
press and investors, Suzanne Beveridge of
Scios Inc., +1-408-616-2947, or +1-408-616-8328; or press, Jim
Weiss of WeissCom Partners, Inc., +1-415-260-1274, or investors,
Fern Lazar or Sara Moorin of Lazar Partners Ltd.,
+1-212-867-1762, all for Scios, Inc.
|
